Quick Answer
LIGAND PHARMACEUTICALS INC reported R&D Expense of $81.18 million for fiscal year 2025.
LIGAND PHARMACEUTICALS INC R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $81.18M | +278.9% |
| 2024 | $21.43M | -12.7% |
| 2023 | $24.54M | -32.0% |
| 2022 | $36.08M | +12.4% |
| 2021 | $32.10M | -20.7% |
| 2020 | $40.50M | -27.6% |
| 2019 | $55.91M | +100.7% |
| 2018 | $27.86M | +3.6% |
| 2017 | $26.89M | +26.7% |
| 2016 | $21.22M | +92.8% |
| 2015 | $11.01M | +12.9% |
| 2014 | $9.75M | +5.1% |
| 2013 | $9.27M | -14.1% |
| 2012 | $10.79M | +4.8% |
| 2011 | $10.29M | -53.4% |
| 2010 | $22.07M | -44.7% |
| 2009 | $39.87M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $21.02M | +270.4% | +220.1% |
| June 30, 2025 | $6.57M | +22.7% | -86.9% |
| March 31, 2025 | $50.09M | +738.8% | +782.6% |
| September 30, 2024 | $5.67M | +2.6% | +6.0% |
| June 30, 2024 | $5.35M | -21.9% | -10.3% |
| March 31, 2024 | $5.97M | -10.4% | +7.9% |
| September 30, 2023 | $5.53M | -40.1% | -19.3% |
| June 30, 2023 | $6.85M | -19.1% | +2.9% |
- LIGAND PHARMACEUTICALS INC showed an increase of +278.9% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, LIGAND PHARMACEUTICALS INC’s r&d expense has grown by 103.6% (from $39.87 million to $81.18 million).
- The most recent figure is from LIGAND PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: